You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
Colorcon
Mallinckrodt
McKinsey

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,447,089

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,447,089 protect, and when does it expire?

Patent 9,447,089 protects ZELBORAF and is included in one NDA.

This patent has sixty-six patent family members in forty-one countries.

Summary for Patent: 9,447,089
Title:Compositions and uses thereof
Abstract: Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluor- o-phenyl}-amide.
Inventor(s): Desai; Dipen (Whippany, NJ), Diodone; Ralph (Breisach, DE), Go; Zenaida (Clifton, NJ), Ibrahim; Prabha N. (Mountain View, CA), Iyer; Raman (Piscataway, NJ), Mair; Hans-Juergen (Loerrach, DE), Sandhu; Harpreet K. (West Orange, NJ), Shah; Navnit H. (Clifton, NJ), Visor; Gary (Castro Valley, CA), Wyttenbach; Nicole (Sissach, CH), Lauper; Stephan (Kaiseraugst, CH), Pudewell; Johannes (Oberwil, CH), Wierschem; Frank (Rheinfelden, CH)
Assignee: Plexxikon Inc. (Berkeley, CA) Hoffman-La Roche Inc. (Nutley, NJ)
Application Number:12/752,035
Patent Claim Types:
see list of patent claims
Compound; Formulation; Dosage form; Composition;

Drugs Protected by US Patent 9,447,089

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,447,089

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
09175665Nov 11, 2009

International Family Members for US Patent 9,447,089

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 078033   Start Trial
Australia 2010232670   Start Trial
Australia 2010318049   Start Trial
Australia 2015238857   Start Trial
Brazil 112012009609   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Colorcon
Express Scripts
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.